These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16263282)

  • 1. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
    Durgam GG; Tsukahara R; Makarova N; Walker MD; Fujiwara Y; Pigg KR; Baker DL; Sardar VM; Parrill AL; Tigyi G; Miller DD
    Bioorg Med Chem Lett; 2006 Feb; 16(3):633-40. PubMed ID: 16263282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
    Durgam GG; Virag T; Walker MD; Tsukahara R; Yasuda S; Liliom K; van Meeteren LA; Moolenaar WH; Wilke N; Siess W; Tigyi G; Miller DD
    J Med Chem; 2005 Jul; 48(15):4919-30. PubMed ID: 16033271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.
    Gududuru V; Zeng K; Tsukahara R; Makarova N; Fujiwara Y; Pigg KR; Baker DL; Tigyi G; Miller DD
    Bioorg Med Chem Lett; 2006 Jan; 16(2):451-6. PubMed ID: 16290140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.
    Xu Y; Jiang G; Tsukahara R; Fujiwara Y; Tigyi G; Prestwich GD
    J Med Chem; 2006 Aug; 49(17):5309-15. PubMed ID: 16913720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
    Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
    Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
    Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
    Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors.
    Fischer DJ; Nusser N; Virag T; Yokoyama K; Wang Da ; Baker DL; Bautista D; Parrill AL; Tigyi G
    Mol Pharmacol; 2001 Oct; 60(4):776-84. PubMed ID: 11562440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.
    Tokumura A; Sinomiya J; Kishimoto S; Tanaka T; Kogure K; Sugiura T; Satouchi K; Waku K; Fukuzawa K
    Biochem J; 2002 Aug; 365(Pt 3):617-28. PubMed ID: 11982483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
    Heasley BH; Jarosz R; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2735-40. PubMed ID: 15125924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood.
    Endo T; Kano K; Motoki R; Hama K; Okudaira S; Ishida M; Ogiso H; Tanaka M; Matsuki N; Taguchi R; Kanai M; Shibasaki M; Arai H; Aoki J
    J Biochem; 2009 Aug; 146(2):283-93. PubMed ID: 19416959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
    Gendaszewska-Darmach E
    Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.
    Khandoga AL; Fujiwara Y; Goyal P; Pandey D; Tsukahara R; Bolen A; Guo H; Wilke N; Liu J; Valentine WJ; Durgam GG; Miller DD; Jiang G; Prestwich GD; Tigyi G; Siess W
    Platelets; 2008 Sep; 19(6):415-27. PubMed ID: 18925509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity.
    Qian L; Xu Y; Hasegawa Y; Aoki J; Mills GB; Prestwich GD
    J Med Chem; 2003 Dec; 46(26):5575-8. PubMed ID: 14667211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
    Gupte R; Siddam A; Lu Y; Li W; Fujiwara Y; Panupinthu N; Pham TC; Baker DL; Parrill AL; Gotoh M; Murakami-Murofushi K; Kobayashi S; Mills GB; Tigyi G; Miller DD
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7525-8. PubMed ID: 21051230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
    Swaney JS; Chapman C; Correa LD; Stebbins KJ; Broadhead AR; Bain G; Santini AM; Darlington J; King CD; Baccei CS; Lee C; Parr TA; Roppe JR; Seiders TJ; Ziff J; Prasit P; Hutchinson JH; Evans JF; Lorrain DS
    J Pharmacol Exp Ther; 2011 Mar; 336(3):693-700. PubMed ID: 21159750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.
    Heasley BH; Jarosz R; Carter KM; Van SJ; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4069-74. PubMed ID: 15225728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dioleoyl phosphatidic acid induces morphological changes through an endogenous LPA receptor in C6 glioma cells.
    Chang YJ; Kim YL; Jo JY; Kyeok K; Kim HL; Im DS
    Arch Pharm Res; 2008 May; 31(5):628-33. PubMed ID: 18481020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors.
    Virag T; Elrod DB; Liliom K; Sardar VM; Parrill AL; Yokoyama K; Durgam G; Deng W; Miller DD; Tigyi G
    Mol Pharmacol; 2003 May; 63(5):1032-42. PubMed ID: 12695531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure--activity relationships of lysophosphatidic acid: conformationally restricted backbone mimetics.
    Hopper DW; Ragan SP; Hooks SB; Lynch KR; Macdonald TL
    J Med Chem; 1999 Mar; 42(6):963-70. PubMed ID: 10090779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs.
    Liliom K; Tsukahara T; Tsukahara R; Zelman-Femiak M; Swiezewska E; Tigyi G
    Biochim Biophys Acta; 2006 Dec; 1761(12):1506-14. PubMed ID: 17092771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.